deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT02681809

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR (CIRCLE)

A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR)

Sponsor: ThromboGenics

Conditions Diabetic Retinopathy Disease Progression Posterior Vitreous Detachment
Interventions Sham injection ocriplasmin 0.0625mg ocriplasmin 0.125mg
Updated 16 times since 2017 Last updated: Dec 8, 2020 Started: Dec 31, 2015 Primary completion: Nov 18, 2019 Completion: Nov 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment rate

Other terminated trials from ThromboGenics

See all terminations from ThromboGenics

Other Diabetic Retinopathy trials with similar outcome

Browse all Diabetic Retinopathy trials

A PHASE2 clinical study on Diabetic Retinopathy and Disease Progression, this trial is terminated or withdrawn. The trial is conducted by ThromboGenics and has accumulated 16 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Oct 2017 · 7 months · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Feb 2020 · 11 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

▶ Show 11 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  3. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

  4. Feb 2020 — Sep 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Mar 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Oct 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  9. Mar 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ThromboGenics
Data source: Oxurion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Beersheba, Israel , Brno, Czechia , Budapest, Hungary , Campbell, United States , Charlottesville, United States , Darmstadt, Germany , Debrecen, Hungary , Frimley, United Kingdom , Girona, Spain and 22 more locations